S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:PBLA

Panbela Therapeutics (PBLA) Stock Price, News & Analysis

$0.42
-0.07 (-14.29%)
(As of 04/19/2024 ET)
Today's Range
$0.40
$0.49
50-Day Range
$0.42
$1.36
52-Week Range
$0.40
$477.00
Volume
263,022 shs
Average Volume
63,870 shs
Market Capitalization
$1.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$500.00

Panbela Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
118,947.6% Upside
$500.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Panbela Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.25) to ($3.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.03 out of 5 stars

PBLA stock logo

About Panbela Therapeutics Stock (NASDAQ:PBLA)

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

PBLA Stock Price History

PBLA Stock News Headlines

Panbela Applies to List on CBOE
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Panbela Announces Transfer to OTCQB Market
Recap: Panbela Therapeutics Q4 Earnings
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Earnings Preview: Panbela Therapeutics
PBLA Panbela Therapeutics, Inc.
Panbela Therapeutics Inc (PBLA)
Panbela Therapeutics Prices $9 Mln Share Offering
Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?
See More Headlines
Receive PBLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
4/21/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PBLA
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$500.00
High Stock Price Target
$500.00
Low Stock Price Target
$500.00
Potential Upside/Downside
+118,947.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-25,260,000.00
Pretax Margin
N/A
Return on Equity
-70,194.55%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($18.37) per share

Miscellaneous

Free Float
3,481,000
Market Cap
$1.46 million
Optionable
Not Optionable
Beta
1.48
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Jennifer K. Simpson CRNP (Age 56)
    M.S.N., Ph.D., CEO, President & Director
    Comp: $527k
  • Ms. Susan Horvath (Age 65)
    VP of Finance, CFO, Secretary & Treasurer
    Comp: $333k
  • Ms. Tammy Groene
    Vice President of Operations
  • Dr. Elizabeth Bruckheimer Ph.D.
    VP & Chief Scientific Officer

PBLA Stock Analysis - Frequently Asked Questions

Should I buy or sell Panbela Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Panbela Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBLA shares.
View PBLA analyst ratings
or view top-rated stocks.

What is Panbela Therapeutics' stock price target for 2024?

2 analysts have issued twelve-month price objectives for Panbela Therapeutics' shares. Their PBLA share price targets range from $500.00 to $500.00. On average, they expect the company's stock price to reach $500.00 in the next twelve months. This suggests a possible upside of 118,947.6% from the stock's current price.
View analysts price targets for PBLA
or view top-rated stocks among Wall Street analysts.

How have PBLA shares performed in 2024?

Panbela Therapeutics' stock was trading at $18.30 at the beginning of the year. Since then, PBLA shares have decreased by 97.7% and is now trading at $0.42.
View the best growth stocks for 2024 here
.

When is Panbela Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PBLA earnings forecast
.

How were Panbela Therapeutics' earnings last quarter?

Panbela Therapeutics, Inc. (NASDAQ:PBLA) released its earnings results on Tuesday, March, 26th. The company reported ($65.90) earnings per share for the quarter, missing the consensus estimate of ($24.34) by $41.56.

When did Panbela Therapeutics' stock split?

Panbela Therapeutics's stock reverse split on Thursday, January 18th 2024. The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Panbela Therapeutics?

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PBLA) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners